Page last updated: 2024-08-17

mannitol and pf 3512676

mannitol has been researched along with pf 3512676 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andrade Filho, PA; Donnenberg, A; Fourcade, J; Janjic, B; Kirkwood, JM; Krieg, A; Kudela, P; Land, SR; Sander, C; Shen, H; Zarour, HM	1
Altorki, NK; Bender, A; Ferrara, CA; Gnjatic, S; Hoffmann, E; Jäger, E; Karbach, J; Neumann, A; Old, LJ; Weidmann, E; Yuan, J	1
Antunes, E; Davis, HL; de Boer, K; Greenberg, PD; Heit, W; Hol, S; Kuball, J; Lotz, C; Theobald, M; van Dorp, S; Vicari, AP; Wagner, E; Wattad, M; Weeratna, RD	1

Trials

2 trial(s) available for mannitol and pf 3512676

Article	Year
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. Journal of immunotherapy (Hagerstown, Md. : 1997), 2008, Volume: 31, Issue:8 Topics: Aged; Aged, 80 and over; Cancer Vaccines; CD8-Positive T-Lymphocytes; Female; Humans; Immunization; Male; Mannitol; Melanoma; Middle Aged; Neoplasm Proteins; Oleic Acids; Oligodeoxyribonucleotides; Peptide Fragments; Pilot Projects; Skin Neoplasms; T-Lymphocytes, Cytotoxic	2008
Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer immunology, immunotherapy : CII, 2011, Volume: 60, Issue:2 Topics: Adolescent; Antigens, Neoplasm; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Humans; Leukemia, Myeloid, Acute; Male; Mannitol; Mucin-1; Multiple Myeloma; Myeloblastin; Neoplasm Staging; Neoplasm, Residual; Oleic Acids; Oligodeoxyribonucleotides; Peptides; Pilot Projects; Treatment Outcome; WT1 Proteins	2011

Article

Year

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.

Journal of immunotherapy (Hagerstown, Md. : 1997), 2008, Volume: 31, Issue:8

Topics: Aged; Aged, 80 and over; Cancer Vaccines; CD8-Positive T-Lymphocytes; Female; Humans; Immunization; Male; Mannitol; Melanoma; Middle Aged; Neoplasm Proteins; Oleic Acids; Oligodeoxyribonucleotides; Peptide Fragments; Pilot Projects; Skin Neoplasms; T-Lymphocytes, Cytotoxic

2008

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

Cancer immunology, immunotherapy : CII, 2011, Volume: 60, Issue:2

Topics: Adolescent; Antigens, Neoplasm; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Humans; Leukemia, Myeloid, Acute; Male; Mannitol; Mucin-1; Multiple Myeloma; Myeloblastin; Neoplasm Staging; Neoplasm, Residual; Oleic Acids; Oligodeoxyribonucleotides; Peptides; Pilot Projects; Treatment Outcome; WT1 Proteins

2011

Other Studies

1 other study(ies) available for mannitol and pf 3512676

Article	Year
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. International journal of cancer, 2010, Feb-15, Volume: 126, Issue:4 Topics: Antigens, Neoplasm; Breast Neoplasms; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Flow Cytometry; Humans; Immunotherapy; Mannitol; Melanoma; Membrane Proteins; Neoplasm Staging; Neoplasms; Oleic Acids; Oligodeoxyribonucleotides; Ovarian Neoplasms; Sarcoma; Vaccination	2010

Article

Year

Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.

International journal of cancer, 2010, Feb-15, Volume: 126, Issue:4

Topics: Antigens, Neoplasm; Breast Neoplasms; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Flow Cytometry; Humans; Immunotherapy; Mannitol; Melanoma; Membrane Proteins; Neoplasm Staging; Neoplasms; Oleic Acids; Oligodeoxyribonucleotides; Ovarian Neoplasms; Sarcoma; Vaccination

2010